GMP manufacturing for exosome-based therapies: the critical role of analytics and process design for clinical production and scale-up
Sep
28
2021
On demand

GMP manufacturing for exosome-based therapies: the critical role of analytics and process design for clinical production and scale-up

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
GMP manufacturing for exosome-based therapies: the critical role of analytics and process design for clinical production and scale-up

When producing exosomes-based therapies, analytics and process design are key to build a successful manufacturing process that keeps you in control of your product for clinical and beyond. There is a fine balance to find, in order to measure appropriately the critical quality attributes of your product, without over-complicating an already complex validation process. During this webinar, our experts will propose a roadmap for EV analytics and process design.

  • Extracellular vesicle biology as new drug modality
  • Analytics for process design and definition of exosome drug substance
  • Manufacturing of exosomes, challenges and opportunities
  • How to establish an effective process for clinical manufacturing and beyond
Marcos Langtry
Marcos Langtry
Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

Davide Zocco
Davide Zocco
Research & Development Senior Manager, Lonza Pharma & Biotech
Davide Zocco has joined Lonza (2020) as senior manager to lead R&D projects for the manufacturing of extracellular vesicles (VEs) within Cell and Gene Therapy Business Unit. He holds the position of Chief Technology Officer at his former company, Exosomics, a Lonza’s strategic R&D partner, to foster the development of protocols and kits for the isolation and characterization of EVs from body fluids. He is author of peer-reviewed publications in high profile journals, including Nature Chemical Biology, PNAS and American Journal of Pathology (>2000 citations), and of three patents in the extracellular vesicle field. He holds a PhD from University College Dublin (Ireland) and he was a postdoctoral research fellow at Harvard Medical School (USA).

SPEAKERS

Marcos Langtry
Marcos Langtry
Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech
Davide Zocco
Davide Zocco
Research & Development Senior Manager, Lonza Pharma & Biotech

You might also like

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Qingrui You, Peiqing Zhang
29 October
Watch
Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Meeting manufacturing demand: robust scale-up of an AAV suspension process to 1,000L

Qingrui You, Peiqing Zhang
26 November
in 3
Days
Register
Optimizing for the future: streamlining the production of T cell-based immunotherapies

Optimizing for the future: streamlining the production of T cell-based immunotherapies

Paula Lam, Soong Poh Loong
30 October
Watch
Accelerate the scale-up to clinical phase: optimizing stem cell culture performance and viral vector titers

Accelerate the scale-up to clinical phase: optimizing stem cell culture performance and viral vector titers

Sara Bursomanno
24 April
Watch
Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Commercial-scale manufacture of lentivirus for ex vivo and in vivo therapies

Rachel Legmann, Michelle Yen Tran
28 March
Watch